Welcome to our dedicated page for Astrotech SEC filings (Ticker: ASTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astrotech Corporation filings document an instrumentation company organized around subsidiaries applying mass spectrometry and gas chromatography to security screening, narcotics detection, agriculture processing, industrial process control, breath analysis, and environmental testing. Results-related 8-K reports include operating updates for product lines such as TRACER 1000 and EN-SCAN.
The filing record also covers security-holder rights under the company's rights agreement, annual meeting voting matters, executive compensation and governance disclosures in proxy materials, officer changes, consulting arrangements, and transaction-related compensation plans. These disclosures describe ASTC's capital structure, board oversight, compensation framework, and material-event reporting obligations.
Astrotech Corporation entered into an at-the-market offering agreement that allows it to sell shares of its common stock with an aggregate offering price of up to $24,492,819 through H.C. Wainwright & Co., LLC. Sales may be made from time to time under the company’s effective Form S-3 shelf registration and a June 2, 2026 prospectus supplement.
Wainwright will act as sales agent and receive a 3.0% commission on the aggregate gross proceeds from each sale. Astrotech is not required to sell any shares, and the program will end when all authorized shares are sold or the agreement is terminated.
Astrotech Corporation is registering an at-the-market offering to sell up to $24,492,819 of its common stock through H.C. Wainwright & Co., LLC as sales agent. The offering permits sales from time to time on the Nasdaq Capital Market at market prices under an Offering Agreement dated June 2, 2026.
The prospectus supplement cites a Sales Agent commission of 3.0%, an example issuance of 538,304 shares at an assumed price of $45.50 (resulting in up to 2,337,603 shares outstanding in that example), and a public float of approximately $73,478,456 based on 1,799,299 shares outstanding as of May 29, 2026.
Wilkinson Tom reported acquisition or exercise transactions in this Form 4 filing.
ASTROTECH Corp director Tom Wilkinson received a grant of 6,006 shares of restricted common stock. The award was made at a price of $0.00 per share and brought his direct holdings to 29,868 shares. All of the restricted shares vested immediately on the grant date.
Winn Charles Arch reported acquisition or exercise transactions in this Form 4 filing.
ASTROTECH Corp director Winn Charles Arch received a grant of 6,006 shares of common stock as equity compensation. The shares were granted as restricted stock under the Astrotech Corporation 2021 Omnibus Equity Incentive Plan and vested in full on the grant date. Following this award, Arch directly holds 9,895 shares of common stock, including 485 shares held in his IRA.
Halinski John William reported acquisition or exercise transactions in this Form 4 filing.
ASTROTECH Corp director John William Halinski received a grant of 6,006 shares of restricted common stock on May 14, 2025 under the Astrotech Corporation 2021 Omnibus Equity Incentive Plan. The award vested in full immediately, bringing his directly held common shares to 9,006 after the grant.
Stober Eric reported acquisition or exercise transactions in this Form 4 filing.
Astrotech Corp director Eric Stober received a grant of 6,006 shares of restricted common stock as equity compensation. The shares were awarded at no cash cost to him and vested 100% immediately on the grant date. After this grant, he directly holds a total of 16,337 Astrotech common shares. This filing reflects a routine stock award under the company’s 2021 Omnibus Equity Incentive Plan rather than an open-market purchase or sale.
MCFARLAND ROBERT N reported acquisition or exercise transactions in this Form 4 filing.
Astrotech Corp director Robert N. McFarland received a grant of 6,006 shares of common stock as equity compensation. The shares were issued as restricted stock under the Astrotech Corporation 2021 Omnibus Equity Incentive Plan at no stated purchase price.
According to the disclosure, 100% of these restricted shares vested immediately on the grant date, meaning McFarland gained full ownership and no ongoing vesting schedule applies to this award. Following the grant, he directly owns a total of 19,906 shares of Astrotech common stock.
Astrotech Corporation reports continued operating losses and shrinking cash as it invests in commercialization of its mass spectrometry platforms. For the three months ended March 31, 2026, revenue was $343,000, down from $534,000 a year earlier, with gross margin falling to 20% from 44% as some older consumables were sold below cost.
Operating expenses declined 14.2% to $3.5 million, but the company still posted a net loss of $3.8 million for the quarter and $11.2 million for the nine‑month period. Cash and cash equivalents were $2.7 million and short‑term investments $3.9 million, supporting working capital of about $9.5 million. Management believes these resources, plus operating cash flows and potential capital‑raising, will fund operations for at least the next 12 months, though substantial additional capital is expected to be needed for longer‑term growth.
Astrotech Corporation reported third-quarter fiscal 2026 results for the period ended March 31, 2026. Revenue for the quarter was $343 thousand compared with $534 thousand a year earlier, generating gross profit of $67 thousand. Operating expenses were $3.52 million, leading to a loss from operations of $3.45 million and a quarterly net loss of $3.77 million, versus $3.63 million in the prior-year quarter.
For the nine months ended March 31, 2026, revenue totaled $787 thousand and net loss was $11.16 million. Cash and cash equivalents were $2.68 million and short-term investments were $3.90 million as of March 31, 2026. Total assets were $16.17 million and total stockholders’ equity was $12.16 million, with an accumulated deficit of $262.03 million. Management highlighted continued cost-efficiency efforts while investing selectively in higher-return areas and advancing a sales pipeline across industrial, safety and trace detection markets.
Astrotech Corporation reported another loss-making quarter while maintaining a solid cash position. For the three months ended December 31, 2025, revenue fell to $148,000 from $261,000, as lower instrument and grant sales outweighed stronger consumables demand. Net loss was $3.9 million, slightly better than the prior year’s $4.0 million, driven mainly by lower operating expenses.
For the six-month period, revenue rose to $445,000 from $295,000, but the company still recorded a $7.4 million net loss. Operating cash outflow was $7.5 million, largely offset by $7.5 million of proceeds from short‑term investments, keeping cash at $3.1 million and short‑term investments at $7.0 million. Working capital stood at about $12.5 million, and management believes existing resources, together with potential equity offerings, can fund operations for at least the next 12 months.
The company continues to invest in commercializing its mass spectrometry platforms across security (TRACER 1000), agriculture (AgLAB 1000-D2), industrial process control (Pro-Control 1000-D2), and new environmental testing products under its EN-SCAN subsidiary. An S‑3 shelf registration was declared effective on January 30, 2026, but no securities have been sold under it yet. As of February 12, 2026, Astrotech had 1,758,953 common shares outstanding.